Sara Leal Siliceo



Yuu EY, Bührer C, Eckmanns T, Fulde M, Herz M, Kurzai O, Lindstedt C, Panagiotou G, Piro VC, Radonic A, Renard BY, Reuss A, Leal Siliceo S, Thielemann N, Thürmer A, van Vorst K, Wieler LH, Haller S# (2024) The gut microbiome, resistome, and mycobiome in preterm newborn infants and mouse pups: lack of lasting effects by antimicrobial therapy or probiotic prophylaxis. Gut Pathogens 16(1), 27.
Chen J*, Leal Siliceo S*, Ni Y, Nielsen HB, Xu A, Panagiotou G (2023) Identification of robust and generalizable biomarkers for microbiome-based stratification in lifestyle interventions. Microbiome 11(1), 178.
Ni Y*, Qian L*, Leal Siliceo S*, Long X*, Nychas E, Liu Y, Ismaiah MJ, Leung H, Zhang L, Gao Q, Wu Q, Zhang Y, Jia Xi, Liu S, Yuan R, Zhou L, Wang X, Li Q, Zhao Y, El-Nezami H, Xu A, Xu G#, Li H#, Panagiotou G#, Jia W# (2023) Resistant starch decreases intrahepatic triglycerides in NAFLD patients via gut microbiome alterations. Cell Metab 35(9), 1530-1547.
Leung H, Long X, Ni Y, Qian L, Nychas E, Siliceo SL, Pohl D, Hanhineva K, Liu Y, Xu A, Nielsen HB, Belda E, Clément K, Loomba R, Li H, Jia W, Panagiotou G (2022) Risk assessment with gut microbiome and metabolite markers in NAFLD development. Sci Transl Med 14(648), eabk0855.